NASDAQ:BTTX

Better Therapeutics Stock Signals

Healthcare > Biotechnology

Buy BTTX

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jul 13, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for Better Therapeutics, Inc.

General

	Signal Type	Signal Value	Data
	Score	0.000	66 days ( 0 %
	Last Price	$0.0001	0 %
Performance History 7 Days $0.0001 $0.0001 0% 30 Days $0.0001 $0.0001 0% 12 Mos $0.0001 $0.0001 0%

8/18

Active Buy Signals

Premium Feature

Specific Signals

Short Term

Net score: 39.19

Signal Type	Signal Value	Importance	Data
High / Low	N/A	Very Low	$0.0001 - $0.0001
Trend - 3 mos	-0.00000056682027 %	High	Width: 0.0000030929215 %
Pred. range - 3 mos	$0.0000999999963 - $0.00009999999942	Low	-0.0000036690332 % - -0.0000005761123 %
Volume Direction	Sell	High	Volume: 422 · Direction: 0
Pivot Short	Sell	Very Low	Jul 10, 2026 - 2 days
RSI Short Pivot Signal	Sell	Very Low	Nov 30, -0001 - N/A days
Short MA 3 mos	Buy	Low	Jun 29, 2026 - 10 days
Long MA 3 mos	Buy	Medium	Jun 29, 2026 - 10 days
Short/Long MA 3 mos	Buy	Medium	Jul 08, 2026 - 4 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now

Long Term

Net score: 57.09

Signal Type	Signal Value	Importance	Data
Trend - 12 mos	1.82 %	Very High	Width: 102.59 %
Pred. range - 12 mos	$0.0001 - $0.0002	High	1.98 % - 106.60 %
Short MA 12 mos	Buy	Very High	Jun 29, 2026 - 10 days
Long MA 12 mos	Sell	Very High	Mar 27, 2026 - 73 days
Short/Long MA 12 mos	Sell	Very High	Apr 24, 2026 - 54 days
Pivot Long	Buy	Low	Jun 25, 2026 - 12 days
RSI Long Pivot Signal	Buy	Low	Apr 16, 2026 - 60 days
Bollinger	Sell	Medium	Nov 30, -0001 - N/A days
MACD	Neutral	High	No Dates Stored For This Signal

Notice: Technical analysis is hidden due to insufficient data.

There can be multiple reasons for our algorithm to not provide conclusion. One of them can be low or no liquidity.

If you think this is not correct, please

ABOUT BETTER THERAPEUTICS, INC.

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also in...

Read Full Profile Here